Cannabis Use among People Entering Drug Treatment in Europe: A Growing Phenomenon?

European Addiction Research

Volumn 23, Issue 3, 2017, Pages 113-121

  Montanari, Linda ^a   Guarita, Bruno ^a   Mounteney, Jane ^a   Zipfel, Nina ^b   Simon, Roland ^a  

^a EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cannabis; Europe; Joinpoint regression; Treatment entries; Trends

Indexed keywords

CANNABIS;

ADULT; CANNABIS USE; CONTROLLED STUDY; DRUG DEPENDENCE; EUROPE; GERMANY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; ITALY; MAJOR CLINICAL STUDY; PATIENT REFERRAL; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; SPAIN; UNITED KINGDOM; CANNABIS ADDICTION; DRUG DEPENDENCE TREATMENT; TRENDS;

CANNABIS; EUROPE; HUMANS; MARIJUANA ABUSE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS;

EID: 85019936566     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000475810     Document Type: Review

References (34)

1. UNODC: World Drug Report 2016. New York, 2016, p 105.
2. European Monitoring Centre for Drugs and Drug Addiction: European Drug Report 2016: Trends and Developments. Lisbon, EMCDDA, 2016., http://www.emcdda.europa.eu/edr2016.
3. EMCDDA: 2016 Statistical Bulletin, 2016.
4. Hall W, Degenhardt L, Lynskey M: Ageing CD of H and: The health and psychological effects of cannabis use. Monogr Ser 2001;182.
5. WHO: The Health and Social Effects of Nonmedical Cannabis Use. 2016. http://who.int/substance-abuse/publications/msbcannabis.pdfua=1.
6. United Nations Office on Drugs and Crimes: Discussion Paper Cannabis A Short Review, 2012, pp 1-29.
7. EMCDDA: A Cannabis Reader: Global Issues and Local Experiences. 2008. http://www.emcdda.europa.eu.
8. EMCDDA: Treatment Demand Indicator Standard Protocol 3.0, 2012.
9. EMCDDA: TDi Methodological Information on 30 European Countries Methods and Definitions of TDi Data Reported to the EMCDDA in 2014, 2014.
10. Schettino J, Leuschner F, Kasten L, Tossman P: Treatment of Cannabis-Related Disorders in Europe. 2015 (http://www.emcdda.europa.eu/attachements.cfm).
11. Institute NC: Joint Point Regression, 2015.
12. Griffiths P, Mounteney J, Laniel L: Understanding changes in heroin availability in Europe over time: Emerging evidence for a slide, a squeeze and a shock. Addiction 2012;107:1539-1540.
13. Rush B, Urbanoski K: Estimating the demand for treatment for cannabis-related problems in Canada. Int J Ment Health Addict 2007;5:181-186.
14. EMCDDA: European Drug Report 2016. Lisbon, EMCDDA, 2016., http://www.emcdda.europa.eu/edr2016.
15. EMCDDA: Annual Report 2005: State of the Drugs Problem in Europe, 2005, p 96.
16. Barrio G, Montanari L, Bravo MJ, Guarita B, de la Fuente L, Pulido J, et al. Trends of heroin use and heroin injection epidemics in Europe: Findings from the EMCDDA treatment demand indicator (TDi). J Subst Abuse Treat 2013;45:19-30.
17. Roxburgh A, Hall WD, Degenhardt L, McLaren J, Black E, Copeland J, et al. The epidemiology of cannabis use and cannabis-related harm in Australia 1993-2007. Addiction 2010;105:1071-1079.
18. Sánchez-Niubò A, Sordo L, Fortiana J, Brugal MT, Domingo-Salvany A: Incidence trends of cannabis and cocaine use from periodic Spanish general population surveys: Effect of standardizing results by age structure. Addiction 2013;108:1450-1458.
19. Spanish National Focal: 2011 Spanish National Report. 2011. http://www.emcdda.europa.eu/html.cfm/index191736EN.html.
20. Kaar SJ, Gao CX, Lloyd B, Smith K, Lubman Di: Trends in cannabis-related ambulance presentations from 2000 to 2013 in Melbourne, Australia. Drug Alcohol Depend 2015;155:24-30.
21. Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 2014;40:1509-1517.
22. Monshouwer K, Smit F, De Graaf R, van Os J, Vollebergh W: First cannabis use: Does onset shift to younger ages Findings from 1988 to 2003 from the Dutch National School Survey on Substance Use. Addiction 2005;100:963-970.
23. European Commission Directorate-General for General Communication: Flash Eurobarometer 401, Young People and Drugs Report, 2014, pp 1-162.
24. Toxicodependência OE da D e: Cannabis production and markets in Europe, Obs Eur da Drog eToxicodependência, 2012, 274.
25. King L: Understanding Cannabis Potency and Monitoring Cannabis Products in Europe, 2008.
26. Niesink RJM, Rigter S, Koeter MW, Brunt TM: Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction 2015;110:1941-1950.
27. EMCDDA: European Monitoring Centre for Drugs and Drug Addiction: Annual Report 2011. The State of the Drugs Problem in Europe, 2011, p 112.
28. Adam C, Raschzok A: Cannabis policy and the uptake of treatment for cannabis-related problems. Drug Alcohol Rev 2017;36:171-177.
29. Winstock AR, Barratt M: Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013;131:106-111.
30. Pirona A, Atkinson A, Sumnall H: Health Responses to New Psychoactive Substances, 2016, p 30.
31. Evren C, Bozkurt M: Synthetic cannabinoids: Crisis of the decade. Dusunen Adam 2013;26:1-11.
32. Montanari L, Guarita B: Polydrug Use among Drug Treatment Clients in Europe. What Implications for Treatment 20 Years of Monitoring-Key Indicators Expert Working Groups, 2015.
33. Degenhardt L, Hall W: Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70.
34. Degenhardt L, Stockings E, Patton G, Hall WD, Lynskey M: The increasing global health priority of substance use in young people. Lancet Psychiatry 2016;3:251-264.